AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Multiple Myeloma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 226 (planned)
- Started
- Dec 5, 2023
- Main results expected
- Jan 24, 2028
- Fully finished
- Jan 24, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Occurrence of dose-limiting toxicity (DLT), as defined in the protocol (Phase Ia dose escalation only)
Measured over: From first dose of AZD0305 until the end of Cycle 1. Cycle 1 (the DLT assessment period is 21 days for Module 1 Group A and 28 days for Module 1 Group B, Module 2, and Module 3)
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over: From time of Informed consent to 30 days post end of treatment
Frequency of dose modifications, dose delays, and treatment discontinuations due to AEs (Module 2 and Module 3)
Measured over: From first dose of study treatment until End of treatment (EOT), assessed up to approximately 2 years (each cycle is 28 days)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06106945 · record last updated 2026-10-30 · checked 2026-11-09 15:47 UTC